The concept of depression as a dysfunction of the immune system

Modern Trends in Pharmacopsychiatry

Volumn 27, Issue , 2010, Pages 53-71

  Leonard, Brian E ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDEPRESSANT AGENT; ATOMOXETINE; CELECOXIB; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; DEXAMETHASONE; GAMMA INTERFERON; RILUZOLE; SEROTONIN; TUMOR NECROSIS FACTOR;

BRAIN FUNCTION; CELLULAR IMMUNITY; CHRONIC STRESS; ELECTROCONVULSIVE THERAPY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOREGULATION; MAJOR DEPRESSION; MOOD CHANGE; NERVE DEGENERATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SIGNAL TRANSDUCTION;

EID: 78649657860     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000319504     Document Type: Review

References (108)

1. Moussavi S, Chatterji E, Verdes A, et al: Depression, chronic disease and decrements in health: results from WHO surveys. Lancet 2007;370:851-858.
2. Murray CJ, Lopez AD: Global mortality and the combination of risk factors: global burden of disease study. Lancet 1997;349:1436-1442.
3. Maes M, Meltzer H, Bosmans E, et al: Increased plasma concentrations of IL-6, sIL-6R, sIL-2R and transferring receptor in major depression. J Affect Disord 1995;34:301-309.
4. Raison CL, Capuron L, Miller AH: Cytokines sing the blues: inflammation and pathogenesis of depression. Trends Immunol 2006;27:24-31.
5. Frasure-Smith N, Lesperance F, Irwin MR, et al: Depression, C-reactive protein and two major cardiac events in men after acute coronary syndromes. Biol Psychiatry 2007;62:302-308.
6. Dantzer R, O'Connor JC, Freund GG, et al: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
7. Quan N, Banks WA: Brain-immune communication pathways. Brain Behav Immun 2007;21:727-735.
8. Dowlati Y, Herrmann N, Swardfager W, et al: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
9. Godbout J P, Berg BM, Krzyszton C, Johnson RW: Alpha-tocopherol attenuates NFκB activation and pro-inflammatory cytokine production in brain improves recovery from lipopolysaccharide induced sickness behaviour. J Neuroimmunol 2005;169:97-105.
10. Raison CL, Borisov AS, Majer M, et al: Activation of central nervous system inflammatory pathways by interferon-alpha: relationship of monoamines an depression. Biol Psychiatry 2009;65:296-303.
11. Si Q, Cosenza M, Kim MO, et al: A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia. J Neurovirol 2004;10:284-292.
12. Anisman H, Merali Z, Hayley S: Neurotransmitters, peptides and cytokines process in relation to depressive disorder: comorbidity between depression and neurodegenerative disorder. Prog Neurobiol Biol Psychiatry 2008;85:1-74.
13. Kitagami T, Yamada K, Miura H, et al: Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain-barrier. Brain Res 2003;978:104-114.
14. Zielasek J, Hartung HP: Molecular mechanisms of microglia activation. Adv Neuroimmunol 1996;6:191-222.
15. Miller AH, Maletic V, Raison CL: Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-741.
16. Moron JA, Zakharova I, Ferrer J V, et al: Mitogen activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003;23:8480-8488.
17. Zhu CB, Blakely RD, Hewlett WA: The proinflammatory cytokines IL-1 beta and TNF-alpha activate serotonin transporters. Neuropsychopharmacology 2006;31:2121-2131.
18. Besedovsky HO, Del Rey A, Klusman I, et al: Cytokines as modulators of the HPA axis. J Steroid Biochem Mol Biol 1991;40:613-618.
19. Pariante CM, Miller AM: Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404.
20. Pace T W, Hu F, Miller AH: Cytokine effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007;21:9-19.
21. Vedder H, Schreiber W, Schuld A, et al: Immuneendocrine host response to endotoxin in major depression. J Psychiatr Res 2007;41:280-289.
22. Bierhaus A, Wolf J, Andrassy N, et al: A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003;100:1920-1925.
23. Reichenberg A, Yirmiya R, Schuld A, et al: Cytokine associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001;58:445-452.
24. O'Connor JC, Lawson MA, Andre C, et al: Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J Immunol 2009;182:3202-3212.
25. O'Connor JC, Andre C, Wang Y, et al: Interferongamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2, 3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009;29:4200-4209.
26. Harrison NA, Brydon L, Walker C, et al: Inflammation causes mood change through alterations in subgenual cingulated activity and mesolimbic connectivity. Biol Psychol 2009;66:407-414.
27. Mazaheri A, McIntosh AR, Mayberg H: Functional connectivity of the rostral cingulated predicts treatment response in unipolar depressives. Biol Psychiatry 2002;51:335.
28. Pace T W, Mietzko TC, Alagbe O, et al: Increased stress induced inflammatory response in male patients with major depression and increased early life stress. Am J Psychiatry 2006;163:1630-1633.
29. McDade TW, Hawkley LC, Cacioppo JT: Psychosocial and behavioral predictors of inflammation in middle-aged and older adults: the Chicago health, aging and social relations study. Psychosom Med 2006;68:376-381.
30. Kielcolt-Glaser JK, Loving TJ, Stowell JR, et al: Hostile marital interactions, proinflammatory cytokine production and wound healing. Arch Gen Psychiatry 2005;62:1377-1384.
31. Frank MG, Baratta M V, Sprunger LR, et al: Microglia serve a neuroimmune substrate for stress-induced potentiation of CNS proinflammatory cytokine response. Brain Behav Immun 2007;21:47-59.
32. Mazzeo RS, Donovan D, Fleshner M, et al: IL-6 response to exercise and high altitude exposure: influence of alpha-adrenergic blockade. J Appl Physiol 2001;91:2143-2149.
33. Pavlov VA, Tracey KJ: The cholinergic anti-inflammatory pathway. Brain Behav Immun 2005;19:493-499.
34. Arana G W, Santos AB, Laraia MT, et al: Dexamethasone for the treatment of depression: a randomized, placebo-controlled, double-blind trial. Am J Psychiatry 1995;152:265-267.
35. McQuade R, Young A H Y: Future therapeutic targets in mood disorders: the glucocorticoid receptor. Br J Psychiatry 2000;177:390-395.
36. Vieira PL, Kalinski P, Wierenga A E A, et al: Glucocorticoids inhibit IL-12p70 production by in vitro generated human dendritic cells without affecting their T cell stimulatory potential. J Immunol 1998;161:5245-5251.
37. Calogero AE, Bagdy G, Moncada ML, D'Agata R: Effect of SSRI agonists on basal CRH and VP induced ACTH release in vitro from rat pituitary cells. J Endocrinol 1993;136:381-387.
38. Davis S, Heal DJ, Stanford SC: Long-lasting effects of an acute stress on the neurochemistry and function of 5-hydroxytryptaminergic neurones in the mouse brain. Psychopharmacology 1995;118:267-272.
39. Myint A-M, Kim Y-K, Verkerk R, et al: Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007;98:143-151.
40. Meijer OC, De Kloet ER: Corticosterone and serotonergic neurotransmission in hippocampus: functional implications of central corticosteroid receptor diversity. Crit Rev Neurobiol 1998;12:1-20.
41. Chaouloff F: Regulation of 5-HT receptors by corticosteroids: where do we stand? Fundam Clin Pharmacol 1995;9:219-233.
42. McKittrick CR, Blanchard DC, Blanchard RJ, et al: Serotonin receptor binding in a colony model of chronic social stress. Biol Psychiatry 1995;37:383-395.
43. Neumeier JC, Petty F, Kramer GL, et al: Learned helplessness increases 5-hydroxytryptamine1B receptor mRNA levels in the rat dorsal raphe nucleus. Biol Psychiatry 1997;41:668-674.
44. Aberg-Wistedt A, Husselmark L, Stain-Malingren R, et al: Serotonergic vulnerability in affective disorder. Acta Psychiatr Scand 1998;97:374-380.
45. O'Keane V, Dinan TG: Prolactin and cortisol responses to d-fenfluramine in major depression: evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 1991;148:1009-1015.
46. Porter R, McAllister-Williams RH, Lunn B, Young A: 5-Hydroxytryptamine receptor function in humans is reduced by acute administration of hydrocortisone. Psychopharmacology 1998;139:243-250.
47. Bernardino L, Agasse F, Silva R, et al: TNF-alpha modulates survival, proliferation and neural differentiation in neonatal sunventricular zone cell cultures. Stem Cells 2008;26:2361-2371.
48. Goshen T, Kreisel H, Ounallah-Saad P, et al: A dual role for IL-1 in hippocampal dependent memory processes. Psychoneuroimmunology 2007;32:1106-1115.
49. Barrientos RM, Sprunger DB, Campeau S, et al: Brain-derived neurotrophic factor mRNA downregulation produced by social isolation is blocked by intrahippocampal interleukin-1 receptor antagonist. Neuroscience 2003;121:847-853.
50. Tilleux S, Hermans E: Neuroinflammation and regulation of glia glutamate uptake in neurological disorders. J Neurosci Res 2007;85:2059-2070.
51. Gavillet M, Allamen I, Magistretti PJ: Modulation of astrocytic metabolic phenotype by proinflammatory cytokines. Glia 2008;56:975-989.
52. Lucassen PJ, Meerlo P, Naylor AS, et al: Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: implications for depression and antidepressant action. Eur Neuropsychopharmacol 2010;20:1-17.
53. Pitt D, Nagelmeier IE, Wilson HC, Raine CS: Glutamate uptake by oligodendrocytes: implications for excitotoxicity in multiple sclerosis. Neurology 2003;61:1113-1120.
54. Hardingham GE, Fukinaga Y, Badinmg H: Extrasynaptic NMDAR's oppose synaptic NMDAR's by triggering CREB shut-off and cell death pathway. Nat Neurosci 2002;5:405-414.
55. Buntinx M, Moreels M, Vandenabeele I, et al: Cytokine induced cell death in human oligodendroglia cell lines: synergistic effects of IFN-gamma and TNF-alpha on apoptosis. Neurosci Res 2004;76:834-845.
56. Myint A-M, Kim Y-K: Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med Hypotheses 2003;61:519-525.
57. Guillemin GJ, Kerr SJ, Smyth GA, et al: The kynurenine pathway metabolism in human astrocytes: pathway for neuroprotection. J Neurochem 2001;78:842-853.
58. Musso T, Gusella GL, Brooks A, et al: Interleukin-4 inhibits indoleamine 2, 3-dioxygenase expression in human monocytes. Blood 1994;83:1408-1411.
59. Stone T W, Darlington LG: Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov 2002;1:609-620.
60. Perkins MN, Stone TW: An iontophoretic investigation of actions of convulsant kynurenines and their interaction with endogenous quinolinic acid. Brain Res 1982;247:184-187.
61. Grant RC, Kapoor V: Murine glial cells regenerate NAD after peroxide induced depletion, using nicotinic acid, nicotinamide or quinolinic acid as substrates. Ann NY Acad Sci 1998;697:53-60.
62. Wichers MC, Kock GH, Robays G, et al: IDO and IFN-alpha induced depressive symptoms: a shift in hypothesis from tryptophan depletion. Mol Psychiatry 2005;10:538-544.
63. Myint A-M, Kim Y-K, Verkerk R, et al: Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007;98:143-151.
64. Sheline YI, Sanghavi MA, Mintum M, Gado MH: Depression duration, but not age, predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999;19:5034-5043.
65. Ongur D, Katz IR, Meyers BS, et al: Glia reduction in subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998;95:13290-13295.
66. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al: Morphometric evidence for neural and glia prefrontal cell pathology in major depression. Biol Psychiatry 1999;45:1085-1098.
67. Leonard BE: Inflammation, depression and dementia: are they connected? Neurochem Res 2007;32:1749-1756.
68. Nibuya M, Takahashi M, Russell DS, Duman RS: Repeated stress increases catalytic TrkB mRNA in rat hippocampus. Neurosci Lett 1999;267:81-84.
69. Maes M, Bosmans E, De Jongh R, et al: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853-858.
70. Dantzer R, O'Connor JC, Freund GG, et al: From inflammation to sickness behaviour: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.
71. Maes M, Yirmyia R, Noraberg J, et al: The inflammatory and neurogenerative hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009;24:27-53.
72. Myint A-M, Leonard BE, Steinbusch H, Kim Y-K: Th1, Th2 and Th3 cytokine alterations in major depression: evidence of impaired neuroprotection. J Affect Disord 2007;98:143-151.
73. Kenis G, Maes M: Effects of antidepressants on the production of cytokines. Int Neuropsychopharmacol 2002;5:401-412.
74. Gordon J, Barnes NM: Lymphocytes transport serotonin and dopamine: agony or ecstasy? Trends Immunol 2003;24:438-443.
75. Taler M, Bar M, Korob I, et al: Evidence for an inhibitory immunomodulatory effect of selected antidepressants on rat splenocytes: possible relevance to depression and hyperactive immune disorders. Int Immunopharmacol 2008;8:526-533.
76. Taler M, Gil-Ad I, Lomnitski L, et al: Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T-lymphocyte function and gene expression. Eur Neuropsychopharmacol 2007;17:744-780.
77. Calabrese JR, Skwerer RG, Barna B, et al: Depression, immunocompetence and prostaglandins of the E series. Psychiatry Res 1986;17:41-47.
78. Linnoila M, Whorton AR, Rubinow DR, et al: CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 1983;40:405-406.
79. Shen Y, Connor TJ, Nolan Y, et al: Differential effects of chronic antidepressant treatments on lipopolysaccharide-induced depression-like behavioural symptoms in the rat. Life Sci 1999;65:1773-1786.
80. Myint A-M, Steinbusch H, Geoghegan L, et al: Effect of the COX-2 inhibitor celecoxib on behavioural and immune changes in the olfactory bulbectomised rat model of depression. Neuro immunomodulation 2007;14:65-71.
81. Hwang J, Zheng LT, Ock J, et al: Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology 2008;55:826-834.
82. Lin Q, Li B, Zhu HY, et al: Clomipramine treatment reversed the glia pathology on a chronic unpredictable stress-induced rat model of depression. Eur Neuropsychopharmacol 2009;19:796-805.
83. Shanker A: Is thymus redundant after adulthood? Immunol Lett 2004;91:79-86.
84. Song C, Earley B, Leonard BE: Effect of chronic treatment with piracetam and tacrine on some changes caused by thymectomy in the rat brain. Pharmacol Biochem Behav 1997;56:697-704.
85. Song C: The effect of thymectomy and IL-1 on memory: implications for the relationship between immunity and depression. Brain Behav Immun 2002;16:557-568.
86. Pitychoutis PM, Griva E, Ioannou K, et al: Chronic antidepressant treatment exerts sexually dimorphic immunomodulatory effects in an experimental model of major depression: do females lack an advantage? Int J Neuropsychopharmacol 2009;12:1157-1163.
87. Kenis G, Maes M: Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002;5:401-412.
88. Lanquillon S, Krieg JC, Bening-Abu-Shach U: Cytokine production and treatment response in major depressive disorder. Neuropsycho pharmacology 2000;22:370-379.
89. O'Sullivan JB, Ryan KM, Curtin NM, et al: Noradrenaline re-uptake inhibitors limit neuroinflammation in rat cortex following a systemic inflammatory challenge: implications for depression and neurodegeneration. Int J Neuropsychopharmacol 2009;12:687-699.
90. Leonard BE, Song C: Stress, depression and the role of cytokines; in Dantzer R (ed): Cytokines, Stress and Depression. New York, Kluwer Academic/Plenum, 1999, pp 251-265.
91. Sluzewska A, Rybakowski J, Bosmans E, et al: Indicators of immune activation in major depression. Psychiatry Res 1996;64:162-167.
92. Wong M-L, Dong C, Maestre-Mesa J, Licinio J: Polymorphisms in inflammation related genes and susceptibility to major depression and antidepressants. Mol Psychiatry 2008;13:800-812.
93. Morrow GR, et al: Differential effects of paroxetine on fatigue and depression: a randomized, doubleblind trial from University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003;21:4635-4641.
94. Lichtenstein GR: Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002;8:237-243.
95. Matthias SD: Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000;22:128-139.
96. Bluthe RM, Dantzer R, Kelley KW: Central mediation of the effects of IL-1 on social exploration and body weight in mice. Psychoneuroendocrinology 1997;22:1-11.
97. Sancora G, Gueorguieva R, Epperson CN, et al: Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004;61:705-713.
98. Mueller N, Schwarz MJ, Dehning A, et al: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a doubleblind, controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-684.
99. Mendlewicz J, Kriwin P, Oswald P, et al: Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation. A pilot open-label study. Int Clin Psychopharmacol 2006;21:227-231.
100. Yedgar S, Krimsky M, Cohen Y, Flower RJ: Treatment of inflammatory disease by selective eicosanoid inhibition: a double-edged sword? Tends Pharmacol Sci 2007;28:459-464.
101. Marchetti B, Abbracchio MP: To be or not to be (inflamed) - Is that the question in anti-inflammatory drug therapy of neurodegenerative disorders? Trends Pharmacol Sci 2005;26:517-525.
102. Choi SH: Cyclooxygenase-1 and-2 enzymes differentially regulate the brain upstream NF-κB pathway and downstream enzymes involved in prostaglandin biosynthesis. J Neurochem 2006;98:801-811.
103. Niwa K: Cyclooxygenase 2 contributes to the functional hyperaemia in whisker barrel cortex. J Neurosci 2000;20:763-770.
104. Yang H, Chen C: Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des 2008;14:1443-1451.
105. Choi SH, Aid S, Bosetti F: The distinct roles of Cox-1 and-2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 2009;30:174-181.
106. Moessner R, Lesch KP: Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998;12:249-271.
107. Moessner R, Heils A, Stoeber G, et al: Enhancement of serotonin transporter function by TNF-alpha but not IL-6. Neurochem Int 1998;33:251-254.
108. Moessner R, Silke D, Schmitt A, et al: Modulation of serotonin transporter function by IL-4. Life Sci 2001;68:873-880.